ATE361370T1 - Verwendung von fak verwandten nicht kinase zur herstellung eines medikaments zur inhibierung der stenose und restnose - Google Patents

Verwendung von fak verwandten nicht kinase zur herstellung eines medikaments zur inhibierung der stenose und restnose

Info

Publication number
ATE361370T1
ATE361370T1 AT04741142T AT04741142T ATE361370T1 AT E361370 T1 ATE361370 T1 AT E361370T1 AT 04741142 T AT04741142 T AT 04741142T AT 04741142 T AT04741142 T AT 04741142T AT E361370 T1 ATE361370 T1 AT E361370T1
Authority
AT
Austria
Prior art keywords
stenosis
fak
medication
kinase
produce
Prior art date
Application number
AT04741142T
Other languages
English (en)
Inventor
Martin Laser
Christof Hauck
Joerg Strotmann
Original Assignee
Bayerische Julius Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayerische Julius Maximilians filed Critical Bayerische Julius Maximilians
Application granted granted Critical
Publication of ATE361370T1 publication Critical patent/ATE361370T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04741142T 2003-07-17 2004-07-19 Verwendung von fak verwandten nicht kinase zur herstellung eines medikaments zur inhibierung der stenose und restnose ATE361370T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03016259 2003-07-17

Publications (1)

Publication Number Publication Date
ATE361370T1 true ATE361370T1 (de) 2007-05-15

Family

ID=34130025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04741142T ATE361370T1 (de) 2003-07-17 2004-07-19 Verwendung von fak verwandten nicht kinase zur herstellung eines medikaments zur inhibierung der stenose und restnose

Country Status (8)

Country Link
US (1) US20070009481A1 (de)
EP (1) EP1644509B1 (de)
JP (1) JP2009513556A (de)
AT (1) ATE361370T1 (de)
DE (1) DE602004006272T2 (de)
ES (1) ES2286644T3 (de)
PL (1) PL1644509T3 (de)
WO (1) WO2005014835A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1984620B (zh) * 2004-04-05 2011-03-30 梅迪沃什有限公司 用于ⅱ型糖尿病患者的生物活性支架
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
WO2015054477A1 (en) 2013-10-09 2015-04-16 The General Hospital Corporation Methods of diagnosing and treating b cell acute lymphoblastic leukemia
EP2982368A1 (de) 2014-08-04 2016-02-10 Universität Konstanz Kleinmolekülige Verbindungen zur Verdrängung von Fokaladhäsions-Kernkomponenten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4509037A (en) * 1981-06-12 1985-04-02 Gould Inc. Enhanced delta modulation encoder
US4737702A (en) * 1982-06-07 1988-04-12 Norand Corporation Battery charging control system particularly for hand held device
US4998109A (en) * 1989-12-13 1991-03-05 Lechevalier Robert E Analog to digital conversion device by charge integration using delay-line time measurement
JP3039809B2 (ja) * 1990-05-31 2000-05-08 株式会社日立製作所 アナログ／ディジタル変換器、サンプリングパルス生成回路、及び電流スイッチ回路
WO1999028750A1 (en) * 1997-12-03 1999-06-10 The University Of North Carolina At Chapel Hill Frnk proteins in the treatment of tumor cells
WO2001009360A1 (en) * 1999-08-02 2001-02-08 Avigen, Inc. USE OF RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR (rAAV) FOR THE PREVENTION OF SMOOTH MUSCLE CELL PROLIFERATION IN A VASCULAR GRAFT
US20020161376A1 (en) * 2001-04-27 2002-10-31 Barry James J. Method and system for delivery of coated implants

Also Published As

Publication number Publication date
DE602004006272D1 (de) 2007-06-14
DE602004006272T2 (de) 2008-01-10
US20070009481A1 (en) 2007-01-11
JP2009513556A (ja) 2009-04-02
EP1644509A1 (de) 2006-04-12
ES2286644T3 (es) 2007-12-01
PL1644509T3 (pl) 2007-10-31
WO2005014835A1 (en) 2005-02-17
EP1644509B1 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
DK1536827T3 (da) Anvendelse af proteinkinase N-beta
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE417876T1 (de) Verfahren zur herstellung von isocyanuratgruppen aufweisenden polyisocyanaten und ihre verwendung
CY1108813T1 (el) Αναστολεις κινασων τυροσινης
ATE481058T1 (de) Dilatations- und stentablagesystem
HUP0000965A2 (hu) Foszfolipáz A2 inhibitor hatású pirrolidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények
CR8268A (es) Compuesto de aril o heteroaril amida como antogonistas del receptor de prostaglandina e2
GT200100132A (es) Derivados de pirazol
ATE414524T1 (de) Verwendung von myoblasten zur herstellung eines medikaments zur behandlung der stressbedingten harninkontinenz
EP2702988A3 (de) Neue Zusammensetzungen und Verfahren zur Behandlung von hyperproliferativen Erkrankungen
EA200600440A1 (ru) 4-((феноксиалкил)тио)еноксиуксусные кислоты и их аналоги
DE60318391D1 (de) Bakteriophagen-lysin
DE60234714D1 (de) Exes zur herstellung eines trockenen aerosol-shampoos
DE502006005290D1 (de) Niedrigviskose uretdiongruppenhaltige polyadditionsverbindungen, verfahren zur herstellung und verwendung
BR0016547A (pt) Composição para a modulação e inibição da permeabilidade vascular (vp)
BRPI0409263A (pt) composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
DE602006018893D1 (de) Anwendung von levo-ornidazol bei der herstellung eines medikaments gegen infektion mit anaeroben bakterien
DE50110618D1 (de) Verwendung von MEK-Inhibitoren zur Herstellung eines Arzneimittels gegen Negativstrang-RNA-Viren Infektionen
DE60335279D1 (de) Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystem

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1644509

Country of ref document: EP